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Background and Purpose—Elevated lipoprotein(a) [Lp(a)] serum levels have been associated with an increased risk of
vascular diseases, and preliminary observations suggest that they are a risk factor for vascular dementia. The relationship
between Lp(a) levels and cognitive performances in the general population has never been investigated. Our aim was
to evaluate the effect of elevated Lp(a) levels on cognitive functions in the elderly.
Methods—Cognitive performances were assessed by means of the Mini-Mental State Examination (MMSE), the Babcock
Short Story, and the Matrix Test in a population sample of 435 white subjects aged 65 to 84 years who were evaluated
at baseline and after 3 years. Lp(a) levels were determined by ELISA.
Results—No statistically significant difference was found in neuropsychological test scores between subjects with and
without elevated Lp(a) levels, although subjects with elevated Lp(a) levels had slightly better cognitive performances.
This difference reached a statistical significance level only in a subscore of the Matrix Test (number of correct
responses) when adjusted for age, sex, education, smoking, and history of stroke. At follow-up, no statistically
significant difference was found in cognitive performances between subjects with and without elevated Lp(a) serum
levels in either univariate or multivariate analyses. Subjects with and without elevated Lp(a) showed a similar decline
rate during follow-up.
Conclusions—In this sample of elderly white subjects, elevated Lp(a) levels were not associated with poorer cognitive
performances or with an increased rate of cognitive decline. Elevated Lp(a) levels do not appear to be a major
determinant of cognitive impairment in the elderly. (Stroke. 2001;32:1678-1683.)
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Lipoprotein(a) [Lp(a)] is a molecule formed by an LDLbound to a glycoprotein called apolipoprotein(a)
[apo(a)].1 Although the physiological function of Lp(a) is still
unknown, elevated Lp(a) serum levels have been found to be
associated with an increased risk of coronary,2–7 peripheral
artery,8,9 and cerebrovascular10–16 diseases. This association
is presumably mediated by the procoagulant17 and the
proatherogenic18 effects of Lp(a).
Because cardiac and cerebrovascular diseases are recog-
nized risk factors for dementia,19,20 the study of Lp(a) in
relation to cognitive functions seemed worthy of investiga-
tion. Although preliminary data from 2 controlled series of
hospitalized patients have indicated that Lp(a) is a possible
risk factor for vascular dementia,21,22 the effect of Lp(a)
levels on cognitive functions has never been investigated in
large population-based surveys.
As part of a study aimed at evaluating the effect of elevated
Lp(a) serum levels on the prevalence of vascular diseases in
an elderly (65 to 84 years old) white population cohort,23 we
were able to study the relationship between Lp(a) levels and
cognitive performances assessed at baseline and after 3 years.
Subjects and Methods
The study was conducted in Impruneta, Florence, which is 1 of the
8 centers participating in the Italian Longitudinal Study on Aging
(ILSA).24,25 ILSA is a population-based, longitudinal study of the
health status of Italians aged 65 to 84 years. The main objective of
ILSA is the study of prevalence and incidence rates of age-related
diseases in the elderly Italian population and the identification of
their risk and protective factors. ILSA is also aimed at assessing
age-associated physical and mental functional changes. All individ-
uals from 65 to 84 years of age who were living at home or
institutionalized and residing in the study areas at the start of the
prevalence study (March 1, 1992) were eligible for inclusion. In each
of the participating centers, a random sample of 704 individuals,
stratified by age and sex, was selected from the demographic records
of the registry office of each municipality according to an equal
allocation strategy: 88 subjects of each sex from 4 age groups (65 to
69, 70 to 74, 75 to 79, and 80 to 84 years).
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Cross-Sectional Study
The prevalence survey was conducted from March 1, 1992, to June
30, 1993. Cases of a given disease were identified in the study cohort
by way of a 2-phase design. In the screening phase, a questionnaire
and a series of brief tests to identify suspect cases for further
investigation were administered to each subject in the sample. In the
confirmation phase, suspect cases were clinically confirmed, and a
differential diagnosis of specific disorders within a syndrome was
formulated. A detailed protocol of the study has been published
elsewhere.24,25
As part of the screening phase, a short battery of neuropsycho-
logical tests was administered by a physician. The tests assessed
global cognitive functions (Mini-Mental State Examination
[MMSE]),26 selective attention [Matrix Test],27 and episodic mem-
ory [immediate and delayed recall of the Babcock Short Story]28).
The Matrix Test (scores range from 0 to 60) has a basic format with
3 different matrices made up of 13 strings of 10 digits (0 to 9 in
random sequence); each line includes 0 to 5 targets, and digits must
be crossed out within a time limit (45 s/matrix). Through a 21-unit
story, the Babcock Short Story (scores range from 0 to 16) measures
immediate and delayed (10 minutes) recall and their sum; an
event-weighed, hierarchical scoring system was used that rewarded
the degree of organization of the subject’s oral recollection.
The presence of cognitive impairment/no dementia (CIND) was
assessed in all the subjects who scored ,24 on the MMSE in the
screening phase. In the ILSA Study, a diagnosis of CIND was made
on the basis of a clinical and neuropsychological examination,
informant interview, and assessment of the subject’s functional
activities. The details of the method are reported elsewhere.29 The
CIND definition is consistent with a more recent one of mild
cognitive impairment.
Characteristics of Subjects Investigated in the
Cross-Sectional Study
The original study cohort was a random population sample, selected
according to the above sampling design in the municipality of
Impruneta, a hilly area on the outskirts of Florence, Italy, that has
15 237 inhabitants, most of whom are engaged in agricultural,
handicrafts, and tertiary activities. On March 1, 1992, the percentage
of persons .65 years of age in this municipality was 16.7%. Of the
total of 704 subjects in the original randomized cohort, 6 died before
the start of the survey and 154 refused (refusal rate 22.06%) to
participate. Due to a delay in starting the Lp(a) assessment, Lp(a)
serum levels were determined in only 446 of the 544 subjects who
had agreed to participate.23 Because the survey was to start with
examination of the oldest subjects first, those who, because of this
delay, missed Lp(a) determination were mainly in the 80- to
84-year-old age group. The mean age of subjects with (n5446) and
without (n5252) Lp(a) determination was 74.565.7 and 75.465.8
years, respectively (t test P50.035), with no significant difference in
sex distribution [among subjects with and without Lp(a) level
assessment, 51.8% and 46.4% were men, respectively; x2 P50.173].
In addition, the subjects who refused to participate in the ILSA
survey were mainly those in the oldest age groups. These exclusions
led to a younger mean age of this study cohort compared with the
original one. We were unable to explore whether further selection
biases occurred in regard to subjects who were lost due to their
refusal to participate in the population survey, because apart from
age and sex, we had no other information related to either determi-
nants or outcomes. On the other hand, we were able to analyze the
differences in the prevalence of risk factors between participants
with Lp(a) determination (n5446) and those who, although partici-
pants of the survey, did not have a Lp(a) determination (n598). No
substantial differences were observed in the prevalence of stroke,
myocardial infarction, angina, or diabetes (x2 P 0.163 to 0.694).
There was only a significant difference in smoking [36.9% versus
20.4% in subjects with and without Lp(a) assessment, respectively;
P50.002] and a trend difference in hypertension [68.5% versus
58.4% in subjects with and without Lp(a) assessment, respectively;
P50.068].
Four hundred thirty-five of 446 subjects with Lp(a) assessment
and 97 of 98 subjects without Lp(a) assessment underwent neuro-
psychological testing. The 97 subjects scored worse than the 435
subjects. As expected, because the subjects without Lp(a) determi-
nation were older, these differences were no longer significant after
correction for age.
Lp(a) Assessment
A blood sample was taken after a 12-hour fast for several laboratory
investigations to determine baseline values. Serum concentration of
Lp(a) was quantified with an ELISA (Biopool).
Normal values of Lp(a) levels are not known for the general
population .65 years of age. Given that a number of studies have
suggested that the risk associated with Lp(a) is confined to the upper
quartile,2,30,31 we chose the 75th percentile as a cutoff to define
subjects with elevated Lp(a) levels. As in another population-based
study,31 in our cohort the 75th percentile differed significantly
between male (310 mg/L) and female (400 mg/L) subgroups;
therefore, the subjects were considered as having elevated Lp(a)
concentration when the level exceeded the 75th percentile for their
sex.
Follow-Up Study
The follow-up survey of the ILSA Study was started on September
1, 1995. Screening and confirmation procedures were the same as
those for the cross-sectional survey. Of the 435 patients with a Lp(a)
determination and a complete neuropsychological examination at
baseline, 49 died before the follow-up neuropsychological evalua-
tion; we were unable to make a comparison between follow-up and
baseline cognitive assessment for an additional 73 subjects who
either were not assessable (n524) or refused to actively participate
in the follow-up study (n549). Thus, 313 subjects were available for
cognitive reexamination.
Statistical Analysis
To examine the effect of Lp(a) on cognitive function, we analyzed
the score differences for each of the 3 tests (MMSE, Matrix Test,
Babcock Short Story) administered in the 2 study phases and
compared the subgroups of subjects within each of the 4 quartiles of
Lp(a) and the 2 subgroups of subjects with and without an elevated
($75th percentile) Lp(a) level. The significance was tested by means
of ANOVA and t test for independent samples, respectively. Because
age, educational level, history of stroke, and smoking were the
factors that had been found to alter cognitive functions in the total
ILSA population,29 we examined the possible confounding or mod-
ifying effect of these factors used as covariate variables in the
ANOVA. We defined as a smoker each subject with a pack-year
index of .10 (pack-years was defined as packs of cigarettes per day
multiplied by the number of years the subject smoked). The
relationship between Lp(a) levels and baseline neuropsychological
test scores was analyzed by means of Pearson’s correlation.
Baseline neuropsychological test scores of the total sample were
compared with the follow-up results, and the statistical significance
of the differences was analyzed by t test for independent samples. All
the scores were also corrected for age, educational level, history of
stroke, smoking, and baseline score (ANOVA).
For the 66 subjects who were unable to complete the MMSE test
at baseline due to motor, visual, or hearing deficits or illiteracy, a
ratio was calculated between the score obtained and the maximum
score obtainable. This ratio was then multiplied by 30 to normalize
it with the scores of other subjects.
The relative prevalence of CIND in subjects with and without
elevated Lp(a) levels was examined, and the statistical significance
assessed by x2 test.
Version 9.0 of SPSS software for Windows was used for these
analyses.32
Results
The demographic characteristics and educational level of the
study cohort are given in Table 1.
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No statistically significant difference was found in neuro-
psychological test scores between the 2 groups of subjects
with ($75th percentile) and without (,75th percentile)
elevated Lp(a) levels, although subjects with elevated Lp(a)
levels had slightly better cognitive performances in all the
tests (Table 2). This difference reached statistical significance
in the number of correct responses in the Matrix Test after
control for age, sex, education, smoking, and history of stroke
(Table 2). No correlation was found between Lp(a) levels and
the neuropsychological test score (Pearson’s correlation P
0.364 to 0.625).
The rate of subjects with elevated Lp(a) levels was equally
distributed in the group of subjects available and in the group
of subjects lost at follow-up (24.9% of available subjects
versus 24.6% of lost subjects). No statistically significant
difference in sex distribution was found (for men, 52.1% of
available subjects versus 53.3% of subjects lost at follow-up,
x2 P50.453). Compared with the 313 available subjects, the
122 subjects lost at follow-up were older (mean age 76.365.8
versus 73.765.6 years, t test P50.0001) and at the cross-
sectional assessment had significantly higher rates of demen-
tia (17.2% versus 2.2%, x2 P,0.001), myocardial infarction
(13.9% versus 7.4%, P50.029), and heart failure (10.7%
versus 1.9%, P,0.001) and nonsignificantly higher rates of
stroke (7.4% versus 3.8%, x2 P50.100) and intermittent
claudication (8.6% versus 5.5%, x2 P50.208).
Table 3 shows the mean test scores among the subgroups
of subjects classified according to the 4 quartiles of Lp(a)
determination. No statistically significant difference was
found in score variations between baseline and follow-up
assessments in each Lp(a) class level.
At follow-up, the neuropsychological test scores showed
no statistically significant difference between subjects with
and without elevated Lp(a) levels at baseline in either the
univariate or the multivariate analysis (Table 4). Table 4 also
shows the differences between the neuropsychological test
scores at baseline and at follow-up assessment. The cognitive
performances of subjects with and without elevated Lp(a)
levels worsened over the follow-up period with a similar
trend.
In our sample, a CIND diagnosis was made in 25 subjects.
No significant difference was found in the prevalence of
CIND between subjects with and without elevated Lp(a)
serum levels (4.9% versus 6.6%, respectively; x2 P50.533).
Discussion
In our population cohort of elderly white subjects, we did not
detect any significant difference in the cognitive perfor-
mances between the groups of subjects with and without
elevated Lp(a) levels. Overall, the slightly better cognitive
profile of subjects with elevated Lp(a) levels detected at
baseline was nonsignificant from a statistical and, in our
opinion, a clinical point of view. Moreover, the significant
difference seen at baseline in a subscore of 1 of the 3
neuropsychological tests was not confirmed at follow-up.
Thus, we conclude that in our population sample, the serum
level of Lp(a) did not influence a subsequent rate of cognitive
decline.
TABLE 1. Demographic Characteristics and Educational Level of Subjects
Lp(a) Level
Total Sample
(n5435) P
,75th Percentile
(n5327)
$75th Percentile
(n5108)
Age, y 74.6265.72 73.9565.82 74.4665.75 0.293*
Male sex, n (%) 172 (52.6) 56 (51.9) 228 (52.4) 0.893†
Education, y 4.5463.50 4.3263.25 4.4963.44 0.575*
*t test.
†x2.
TABLE 2. Baseline Neuropsychological Test Scores (Mean6SD) According to
Serum Level of Lp(a)
Lp(a) Level
P * P†
,75th Percentile
(n5327)
$75th Percentile
(n5108)
MMSE 25.3664.4 26.0463.7 0.155 0.064
Babcock Short Story
Immediate recall 4.2862.3 4.4662.3 0.478 0.251
Delayed recall 4.9162.6 5.3662.4 0.114 0.072
Matrix Test
Correct responses 35.67612.4 38.34612.6 0.062 0.005
Omissions 11.0167.2 11.0768.1 0.948 0.699
False alarms 0.2760.9 0.2661.2 0.936 0.205
Values are mean6SD.
*Univariate analysis (t test).
†Adjustment for age, education, history of stroke, and smoking (ANOVA).
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Because elevated Lp(a) levels have been reported to be
associated with an increased risk of coronary artery and
cerebrovascular diseases, our original hypothesis was that an
elevated Lp(a) level could also be a risk factor for poorer
cognitive performances. Although a previous study on the
same population did not disclose any association between
elevated Lp(a) levels and vascular diseases,23 we decided to
analyze the effect of elevated Lp(a) levels on cognitive
TABLE 3. Neuropsychological Test Scores According to Lp(a) Level Quartiles at
Baseline and Follow-Up
Neuropsychological Test
Lp(a) Level
Quartile Baseline P * Follow-Up P *
MMSE ,25th 26.064.0 25.164.9
25th–50th 25.064.8 0.142 24.465.0 0.254
50th–75th 25.064.5 24.365.5
.75th 26.063.7 25.764.0
Babcock Short Story
Immediate recall ,25th 4.761.9 4.462.1
25th–50th 4.262.4 0.176 3.962.2 0.192
50th–75th 4.062.5 4.062.1
.75th 4.562.3 4.562.1
Delayed recall ,25th 5.362.3 4.762.3
25th–50th 4.762.7 0.139 4.562.5 0.274
50th–75th 4.862.7 4.962.0
.75th 5.462.4 5.262.2
Matrix Test
Correct responses ,25th 37.8613.7 35.7613.2
25th–50th 34.5610.6 0.049 35.8611.5 0.500
50th–75th 34.8612.6 36.2613.0
.75th 38.3612.6 38.6612.3
Omissions ,25th 9.866.8 8.766.1
25th–50th 11.566.9 0.294 9.766.3 0.715
50th–75th 11.667.9 9.766.0
.75th 11.067.4 9.266.4
False alarms ,25th 0.2260.7 0.3661.1
25th–50th 0.2560.7 0.798 0.2561.0 0.696
50th–75th 0.3561.0 0.1960.6
.75th 0.2661.2 0.2360.7
Values are mean6SD.
*ANOVA.
TABLE 4. Cognitive Performances in Subjects Available at Follow-Up and Differences Versus Baseline
Lp(a) Level
,75th Percentile
(n5235)
Lp(a) Level
$75th Percentile
(n578) P * P†
DLp(a) ,75th
Percentile
DLp(a) $75th
Percentile P * P†
MMSE 24.6465.1 25.7064.0 0.098 0.823 1.663.8 1.463.1 0.682 0.823
Babcock Short Story
Immediate recall 4.0562.1 4.4762.1 0.144 0.119 0.562.2 0.361.8 0.541 0.162
Delayed recall 4.6662.3 5.162.3 0.157 0.114 0.660.6 0.660.6 0.827 0.175
Matrix Test
Correct responses 36.08612.4 38.11612.7 0.238 0.284 1.467.3 2.967.2 0.123 0.284
Omissions 9.4866.2 9.4266.5 0.945 0.443 1.165.9 0.567.0 0.506 0.443
False alarms 0.2660.9 0.2060.7 0.588 0.568 20.161.0 0.161.5 0.225 0.568
Values are mean6SD.
D indicates differences between baseline and follow-up scores.
*Univariate analysis (t test).
†Adjustment for age, education, history of stroke, smoking, and baseline score (ANOVA).
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functions for the possibility that silent cerebrovascular dis-
ease (not assessable because the ILSA protocol does not
include a neuroimaging evaluation) might be found in this
population. There are at least 2 studies that show an associ-
ation between elevated Lp(a) levels and silent cerebral
infarction33 or subcortical vascular encephalopathy.34 The
results of our study on an aged (.65 years) cohort do not
support the original hypothesis. One should bear in mind,
however, that the association between vascular diseases and
elevated Lp(a) has been found mainly in subjects ,60 years
of age35–38 and that elevated Lp(a) levels alone did not
represent, as in our cohort, a risk factor for vascular diseas-
es.23 Thus, the putative detrimental effect of Lp(a) on cogni-
tive performance could be similarly undetectable in older
subjects of the general population. Because apo(a) molecular
weight has been recently regarded as the main determinant of
the harmful effect of Lp(a),39 it could be hypothesized that
subjects with elevated Lp(a) levels who survive to older age
carry a less risky type of Lp(a) and thus are protected from its
deleterious effect.
To the best of our knowledge, this study is the first to have
evaluated the effect of Lp(a) levels on cognitive perfor-
mances in the general population. In 2 Japanese studies,21,22
elevated Lp(a) levels were found to be a risk factor for
dementia. In the first study, higher Lp(a) levels were ob-
served in patients with vascular dementia and large artery
stroke compared with patients with Alzheimer’s dementia,
cerebral hemorrhage, and lacunar infarcts.21 In the second
study, the Lp(a) levels of patients with cerebrovascular
disease and dementia were higher than those of age-matched
control subjects.22 Both studies focused on vascular dementia
and used hospital-based patient series. In our population
study, Lp(a) levels did not appear to influence the prevalence
or subsequent rate of dementia, but we had a very small
number of cases and we chose not to present these data. In our
sample, only 1 of 6 subjects with a diagnosis of vascular
dementia had an elevated Lp(a) level.
On the other hand, the influence of Lp(a) levels on
cognitive performances in whites has not been previously
investigated. As shown in a biracial population study,40,41 the
effect of elevated Lp(a) serum levels on vascular diseases
may be dissimilar in different races: compared with whites,
blacks have twice as high mean Lp(a) levels but carry the
same or even a lower disease risk. One can assume that the
effect of Lp(a) on cognition may also vary according to race.
Concerning the methodological issues of our study, Lp(a)
was not assessed in nonresponders (the nonresponse rate of
20% can be considered acceptable for such population-based
surveys) and in the previously mentioned group of individu-
als because of the delay in Lp(a) determination. Both these
circumstances lowered the mean age of the study cohort due
to the exclusion of older subjects but probably did not result
in a systematic selection bias. In fact, apart from age and
smoking, there was no difference in the prevalence of the
diseases and risk factors being investigated between the
group of subjects with and without Lp(a) level determination.
The multivariate analysis showed that the worse neuropsy-
chological performances of subjects without Lp(a) determi-
nation were mainly due to their older age.
We arbitrarily chose the 75th percentile to separate sub-
jects with and without an elevated Lp(a) level. This was
supported by data showing that the vascular risk associated
with Lp(a) is confined to the upper quartile.2,30,31 The 75th
percentile for Lp(a) level in our study was slightly higher than
that of previously quoted studies, and therefore it is unlikely
that it could be below a putatively dangerous level. A repeat
of the same analyses with the 70th, 80th, and 90th percentile
cutoff limits or with a common 75th percentile for men and
women did not change the significance of the results.
The battery of neuropsychological tests used to evaluate
cognitive performances in this population sample originated
from the general protocol of the ILSA Study.24 This protocol
included the MMSE along with the Babcock Short Story and
the Matrix Test to screen subjects in this population suspected
of having mental decline. The MMSE was chosen because it
is the test most widely used and validated for the neuropsy-
chological screening of large population-based studies. The
choice of the other 2 tests was dictated by the need to expand
the exploration of cognitive functions omitted by the MMSE
and by these tests being rather easily administered in terms of
time and compliance by the subjects under investigation (also
in consideration of the low educational level of this Italian
65- to 84-year-old age group). Although the screening battery
of tests used in the ILSA Study cannot be regarded as
comprehensive (information regarding selective dysfunction
related to age such as language and planning capacity is
lacking), the Matrix Test and the Babcock Short Story are
highly focused in finding alterations in attention and episodic
memory, respectively. However, we cannot exclude that the
use of a more comprehensive battery of neuropsychological
tests and a longer follow-up period would have led to
different results.
In conclusion, according to our data, elevated Lp(a) levels
cannot be considered among the factors that influence cog-
nitive performances in elderly whites. Future longitudinal
observation studies should be aimed at evaluating the role of
Lp(a) in relation to cognitive performances in younger age
groups and in different racial groups.
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